Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Leases (2019 - 2025)

Guided Therapeutics (GTHP) has disclosed Current Leases for 7 consecutive years, with $45000.0 as the latest value for Q4 2025.

  • Quarterly Current Leases fell 57.55% to $45000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45000.0 through Dec 2025, down 57.55% year-over-year, with the annual reading at $45000.0 for FY2025, 57.55% down from the prior year.
  • Current Leases hit $45000.0 in Q4 2025 for Guided Therapeutics, down from $76000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $110000.0 in Q1 2025 to a low of $42000.0 in Q1 2021.
  • Historically, Current Leases has averaged $80800.0 across 5 years, with a median of $80500.0 in 2022.
  • Biggest five-year swings in Current Leases: crashed 57.58% in 2021 and later skyrocketed 66.67% in 2022.
  • Year by year, Current Leases stood at $67000.0 in 2021, then grew by 17.91% to $79000.0 in 2022, then rose by 15.19% to $91000.0 in 2023, then grew by 16.48% to $106000.0 in 2024, then crashed by 57.55% to $45000.0 in 2025.
  • Business Quant data shows Current Leases for GTHP at $45000.0 in Q4 2025, $76000.0 in Q3 2025, and $104000.0 in Q2 2025.